- Home
- HKIT vs RFL Comparison
HKIT vs RFL Comparison
Compare HKIT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKIT
- RFL
- Stock Information
- Founded
- HKIT 1996
- RFL 2017
- Country
- HKIT China
- RFL United States
- Employees
- HKIT N/A
- RFL N/A
- Industry
- HKIT Computer Software: Prepackaged Software
- RFL Real Estate
- Sector
- HKIT Technology
- RFL Finance
- Exchange
- HKIT Nasdaq
- RFL Nasdaq
- Market Cap
- HKIT 45.4M
- RFL 48.4M
- IPO Year
- HKIT 2023
- RFL N/A
- Fundamental
- Price
- HKIT $1.50
- RFL $2.40
- Analyst Decision
- HKIT
- RFL
- Analyst Count
- HKIT 0
- RFL 0
- Target Price
- HKIT N/A
- RFL N/A
- AVG Volume (30 Days)
- HKIT 33.7K
- RFL 65.0K
- Earning Date
- HKIT 11-07-2024
- RFL 12-12-2024
- Dividend Yield
- HKIT N/A
- RFL N/A
- EPS Growth
- HKIT N/A
- RFL N/A
- EPS
- HKIT 0.08
- RFL N/A
- Revenue
- HKIT $4,563,731.00
- RFL $540,000.00
- Revenue This Year
- HKIT N/A
- RFL N/A
- Revenue Next Year
- HKIT N/A
- RFL N/A
- P/E Ratio
- HKIT $18.86
- RFL N/A
- Revenue Growth
- HKIT N/A
- RFL 92.86
- 52 Week Low
- HKIT $0.54
- RFL $1.29
- 52 Week High
- HKIT $6.48
- RFL $2.44
- Technical
- Relative Strength Index (RSI)
- HKIT 50.40
- RFL 87.25
- Support Level
- HKIT $1.39
- RFL $2.00
- Resistance Level
- HKIT $1.79
- RFL $1.94
- Average True Range (ATR)
- HKIT 0.13
- RFL 0.10
- MACD
- HKIT 0.00
- RFL 0.03
- Stochastic Oscillator
- HKIT 34.48
- RFL 94.85
About HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.